The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
Open Access
- 15 June 2020
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 10 (6), 912
- https://doi.org/10.3390/biom10060912
Abstract
Biomarkers and disease-modifying therapies are both urgent unmet medical needs in the treatment of Parkinson’s disease (PD) and must be developed concurrently because of their interdependent relationship: biomarkers for the early detection of disease (i.e., prior to overt neurodegeneration) are necessary in order for patients to receive maximal therapeutic benefit and vice versa; disease-modifying therapies must become available for patients whose potential for disease diagnosis and prognosis can be predicted with biomarkers. This review provides an overview of the milestones achieved to date in the therapeutic strategy development of disease-modifying therapies and biomarkers for PD, with a focus on the most common and advanced genetically linked targets alpha-synuclein (SNCA), leucine-rich repeat kinase-2 (LRRK2) and glucocerebrosidase (GBA1). Furthermore, we discuss the convergence of the different pathways and the importance of patient stratification and how these advances may apply more broadly to idiopathic PD. The heterogeneity of PD poses a challenge for therapeutic and biomarker development, however, the one gene- one target approach has brought us closer than ever before to an unprecedented number of clinical trials and biomarker advancements.Funding Information
- HFRI (1855)
- Parkinson Foundation (1897)
This publication has 169 references indexed in Scilit:
- Caudo‐rostral brain spreading of α‐synuclein through vagal connectionsEMBO Molecular Medicine, 2013
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson’s Disease-Related Toxicity in Human NeuronsACS Chemical Biology, 2011
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- SNCA Variant Associated With Parkinson Disease and Plasma α-Synuclein LevelArchives of Neurology, 2010
- Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localizationBiochemical Journal, 2010
- 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationBiochemical Journal, 2010
- Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's diseaseNeuroscience Letters, 2010
- Genome-wide association study reveals genetic risk underlying Parkinson's diseaseNature Genetics, 2009